EGFR and pancreatic neoplasm: We report that in cultured human and mouse pancreatic cancer cells, exogenous GH treatment partially rescues tumor cells from the cytotoxic effects of chemotherapies—gemcitabine, doxorubicin, and the EGFR-inhibitor, erlotinib (Figure S9).